Low Molecular Weight Heparin Market - by Drug Type (Enoxaparin, Dalteparin, Tinzaparin, and Others), by Application (Venous Thromboembolism, Myocardial Infraction, Complicated Pregnancies, Cardioversion of Atrial Fibrillation, and Others), and by Distribu

Low Molecular Weight Heparin Market - by Drug Type (Enoxaparin, Dalteparin, Tinzaparin, and Others), by Application (Venous Thromboembolism, Myocardial Infraction, Complicated Pregnancies, Cardioversion of Atrial Fibrillation, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis 2017-2025

Low Molecular Weight Heparin (LMWH) has several advantages over other heparin such as longer and more predictable activity than Unfractionated Heparin (UFH) and can be self-administrated at home via subcutaneous injection, reducing or eliminating hospital stays, thereby no regular blood monitoring required. Furthermore, heparins do not cross the placenta or harm the fetus, so they are the preferred anticoagulants for pregnant women who experience or who are at heightened risk of – blood clots. These advantages make LMWH as the most preferred heparin in inhibiting clotting factors.

Market Dynamics

Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for LMWH. For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), February 2018; the precise number of people affected by DVT/PE is unknown, although as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the U.S.

Furthermore, increasing engagement of government healthcare regulatory bodies in developing and delivering effective and cost-effective low molecular weight heparin molecule products in the market is expected to propel the growth of the market. For instance, in 2014, American Society of Health-System Pharmacists (ASHP) issued the policy for safe and effective use of heparin in neonatal patients thereby supporting the development and use of nationally standardized concentrations of heparin when used for maintenance and flush of peripheral and central venous lines in neonatal patients.

Key features of the study:

• This report provides in-depth analysis of low molecular weight heparin market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
• It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, low molecular weight heparin approval & launch, regional outlook, and competitive strategy adopted by key players
• It profiles key players in the global low molecular weight heparin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
• Key companies covered as part of this study include, Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future drug launch, manufacturing up-gradation, market expansion, and marketing tactics
• The global low molecular weight heparin market report caters to various stakeholders in this industry including investors, suppliers, low molecular weight heparin based product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the low molecular weight heparin market.

Detailed Segmentation:

• Global Low Molecular Weight Heparin Market, By Drug:
• Enoxaparin
• Dalteparin
• Nadroparin
• Bemiparin
• Tinzaparin
• Others
• Global Low Molecular Weight Heparin Market, By Packaging:
• Multi-vials
• Prefilled Syringes
• Global Low Molecular Weight Heparin Market, By Application:
• Deep Vein Thrombosis
• Acute Coronary Syndrome (ACS)
• Pulmonary Embolism
• Atrial Fibrillation
• Global Low Molecular Weight Heparin Market, By End Use:
• Hospitals
• Private
• Public
• Clinics
• Home
• Global Low Molecular Weight Heparin Market, By Geography:
• North America
• By Country:
• U.S.
• Canada
• By Drug:
• Enoxaparin
• Dalteparin
• Nadroparin
• Bemiparin
• Tinzaparin
• Others
• By Packaging
• Multi-vials
• Prefilled Syringes
• By Application:
• Deep Vein Thrombosis
• Acute Coronary Syndrome (ACS)
• Pulmonary Embolism
• Atrial Fibrillation
• By End Use:
• Hospitals
• Private
• Public
• Clinics
• Home
• Europe
• By Country:
• Germany
• France
• Italy
• UK
• Spain
• Russia
• Rest of Europe
• By Drug:
• Enoxaparin
• Dalteparin
• Nadroparin
• Bemiparin
• Tinzaparin
• Others
• By Packaging
• Multi-vials
• Prefilled Syringes
• By Application:
• Deep Vein Thrombosis
• Acute Coronary Syndrome (ACS)
• Pulmonary Embolism
• Atrial Fibrillation
• By End Use:
• Hospitals
• Private
• Public
• Clinics
• Home
• Asia Pacific
• By Country:
• China
• India
• Japan
• South Korea
• Australia
• Rest of Asia Pacific
• By Drug:
• Enoxaparin
• Dalteparin
• Nadroparin
• Bemiparin
• Tinzaparin
• Others
• By Packaging
• Multi-vials
• Prefilled Syringes
• By Application:
• Deep Vein Thrombosis
• Acute Coronary Syndrome (ACS)
• Pulmonary Embolism
• Atrial Fibrillation
• By End Use:
• Hospitals
• Private
• Public
• Clinics
• Home
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• By Drug:
• Enoxaparin
• Dalteparin
• Nadroparin
• Bemiparin
• Tinzaparin
• Others
• By Packaging
• Multi-vials
• Prefilled Syringes
• By Application:
• Deep Vein Thrombosis
• Acute Coronary Syndrome (ACS)
• Pulmonary Embolism
• Atrial Fibrillation
• By End Use:
• Hospitals
• Private
• Public
• Clinics
• Home
• Latin America
• By Country:
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• By Drug:
• Enoxaparin
• Dalteparin
• Nadroparin
• Bemiparin
• Tinzaparin
• Others
• By Packaging
• Multi-vials
• Prefilled Syringes
• By Application:
• Deep Vein Thrombosis
• Acute Coronary Syndrome (ACS)
• Pulmonary Embolism
• Atrial Fibrillation
• By End Use:
• Hospitals
• Private
• Public
• Clinics
• Home
• Africa
• By Country:
• South Africa
• Central Africa
• North Africa
• By Drug:
• Enoxaparin
• Dalteparin
• Nadroparin
• Bemiparin
• Tinzaparin
• Others
• By Packaging
• Multi-vials
• Prefilled Syringes
• By Application:
• Deep Vein Thrombosis
• Acute Coronary Syndrome (ACS)
• Pulmonary Embolism
• Atrial Fibrillation
• By End Use:
• Hospitals
• Private
• Public
• Clinics
• Home
• Company Profiles
• Pfizer, Inc.*
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments
• Strategies
• LEO Pharma A/S
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Amphastar Pharmaceuticals Inc.
• Abbott Laboratories
• Aspen Pharmacare Holdings
• Laboratorios Farmaceuticos ROVI SA
• Changzhou Qianhong Biopharma
• Intrapharm Laboratories

“*” marked represents similar segmentation in other categories in the respective section.